Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids

Bibliographic Details
Main Author: Loureiro, Liliana R.
Publication Date: 2018
Other Authors: Sousa, Diana P., Ferreira, Dylan, Chai, Wengang, Lima, Luís Carlos Oliveira, Pereira, Carina, Lopes, Carla B., Correia, Viviana G., Silva, Lisete M., Li, Chunxia, Santos, Lúcio Lara, Ferreira, José Alexandre, Barbas, Ana, Palma, Angelina S., Novo, Carlos, Videira, Paula A.
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10362/147031
Summary: This work was supported by the Bluepharma innovation award "Trifunctional antibodies and dendritic cell-based technologies: a combined approach to cancer immunotherapy" 2013 and the Scientific merit prize Santander - Totta - Lisbon New University - "Antibody engineering for breast cancer therapy" 2013. LRL is supported by the grant PD/BD/52476/2013 from the Portuguese Foundation for Science and Technology (FCT). The work is partially supported by FCT-MCTES through the grants IF/00033/2012 (ASP), SFRH/BPD/101827/2014 (LL) and SFRH/BPD/111048/2015 (JAF), the Wellcome Trust Biomedical Resource grant (WC) and the NSFC-Shandong Joint Fund (U1606403) (CL). The authors also acknowledge FCT funding for CI-IPOP research unit (PEst-OE/SAU/UI0776/201). co-financed by the European Regional Development Fund under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). FCT is co-financed by European Social Fund (ESF) under Human Potential Operation Programme (POPH) from National Strategic Reference Framework (NSRF). The funders did not play a role in the study design, data collection or decision to publish.
id RCAP_874b42fa3c20a9274bd814a96b6da700
oai_identifier_str oai:run.unl.pt:10362/147031
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acidsGeneralSDG 3 - Good Health and Well-beingThis work was supported by the Bluepharma innovation award "Trifunctional antibodies and dendritic cell-based technologies: a combined approach to cancer immunotherapy" 2013 and the Scientific merit prize Santander - Totta - Lisbon New University - "Antibody engineering for breast cancer therapy" 2013. LRL is supported by the grant PD/BD/52476/2013 from the Portuguese Foundation for Science and Technology (FCT). The work is partially supported by FCT-MCTES through the grants IF/00033/2012 (ASP), SFRH/BPD/101827/2014 (LL) and SFRH/BPD/111048/2015 (JAF), the Wellcome Trust Biomedical Resource grant (WC) and the NSFC-Shandong Joint Fund (U1606403) (CL). The authors also acknowledge FCT funding for CI-IPOP research unit (PEst-OE/SAU/UI0776/201). co-financed by the European Regional Development Fund under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). FCT is co-financed by European Social Fund (ESF) under Human Potential Operation Programme (POPH) from National Strategic Reference Framework (NSRF). The funders did not play a role in the study design, data collection or decision to publish.Incomplete O-glycosylation is a feature associated with malignancy resulting in the expression of truncated glycans such as the sialyl-Tn (STn) antigen. Despite all the progress in the development of potential anti-cancer antibodies, their application is frequently hindered by low specificities and cross-reactivity. In this study, a novel anti-STn monoclonal antibody named L2A5 was developed by hybridoma technology. Flow cytometry analysis showed that L2A5 specifically binds to sialylated structures on the cell surface of STn-expressing breast and bladder cancer cell lines. Moreover, immunoblotting assays demonstrated reactivity to tumour-associated O-glycosylated proteins, such as MUC1. Tumour recognition was further observed using immunohistochemistry assays, which demonstrated a high sensitivity and specificity of L2A5 mAb towards cancer tissue, using bladder and colorectal cancer tissues. L2A5 staining was exclusively tumoural, with a remarkable reactivity in invasive and metastasis sites, not detectable by other anti-STn mAbs. Additionally, it stained 20% of cases of triple-negative breast cancers, suggesting application in diseases with unmet clinical needs. Finally, the fine specificity was assessed using glycan microarrays, demonstrating a highly specific binding of L2A5 to core STn antigens and additional ability to bind 2–6-linked sialyl core-1 probes. In conclusion, this study describes a novel anti-STn antibody with a unique binding specificity that can be applied for cancer diagnostic and future development of new antibody-based therapeutic applications.UCIBIO - Applied Molecular Biosciences UnitDCV - Departamento de Ciências da VidaDQ - Departamento de QuímicaRUNLoureiro, Liliana R.Sousa, Diana P.Ferreira, DylanChai, WengangLima, Luís Carlos OliveiraPereira, CarinaLopes, Carla B.Correia, Viviana G.Silva, Lisete M.Li, ChunxiaSantos, Lúcio LaraFerreira, José AlexandreBarbas, AnaPalma, Angelina S.Novo, CarlosVideira, Paula A.2023-01-05T22:13:24Z2018-12-012018-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/147031eng2045-2322PURE: 16666184https://doi.org/10.1038/s41598-018-30421-winfo:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2024-10-07T01:36:58Zoai:run.unl.pt:10362/147031Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T17:38:19.540120Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
title Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
spellingShingle Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
Loureiro, Liliana R.
General
SDG 3 - Good Health and Well-being
title_short Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
title_full Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
title_fullStr Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
title_full_unstemmed Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
title_sort Novel monoclonal antibody L2A5 specifically targeting sialyl-Tn and short glycans terminated by alpha-2–6 sialic acids
author Loureiro, Liliana R.
author_facet Loureiro, Liliana R.
Sousa, Diana P.
Ferreira, Dylan
Chai, Wengang
Lima, Luís Carlos Oliveira
Pereira, Carina
Lopes, Carla B.
Correia, Viviana G.
Silva, Lisete M.
Li, Chunxia
Santos, Lúcio Lara
Ferreira, José Alexandre
Barbas, Ana
Palma, Angelina S.
Novo, Carlos
Videira, Paula A.
author_role author
author2 Sousa, Diana P.
Ferreira, Dylan
Chai, Wengang
Lima, Luís Carlos Oliveira
Pereira, Carina
Lopes, Carla B.
Correia, Viviana G.
Silva, Lisete M.
Li, Chunxia
Santos, Lúcio Lara
Ferreira, José Alexandre
Barbas, Ana
Palma, Angelina S.
Novo, Carlos
Videira, Paula A.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv UCIBIO - Applied Molecular Biosciences Unit
DCV - Departamento de Ciências da Vida
DQ - Departamento de Química
RUN
dc.contributor.author.fl_str_mv Loureiro, Liliana R.
Sousa, Diana P.
Ferreira, Dylan
Chai, Wengang
Lima, Luís Carlos Oliveira
Pereira, Carina
Lopes, Carla B.
Correia, Viviana G.
Silva, Lisete M.
Li, Chunxia
Santos, Lúcio Lara
Ferreira, José Alexandre
Barbas, Ana
Palma, Angelina S.
Novo, Carlos
Videira, Paula A.
dc.subject.por.fl_str_mv General
SDG 3 - Good Health and Well-being
topic General
SDG 3 - Good Health and Well-being
description This work was supported by the Bluepharma innovation award "Trifunctional antibodies and dendritic cell-based technologies: a combined approach to cancer immunotherapy" 2013 and the Scientific merit prize Santander - Totta - Lisbon New University - "Antibody engineering for breast cancer therapy" 2013. LRL is supported by the grant PD/BD/52476/2013 from the Portuguese Foundation for Science and Technology (FCT). The work is partially supported by FCT-MCTES through the grants IF/00033/2012 (ASP), SFRH/BPD/101827/2014 (LL) and SFRH/BPD/111048/2015 (JAF), the Wellcome Trust Biomedical Resource grant (WC) and the NSFC-Shandong Joint Fund (U1606403) (CL). The authors also acknowledge FCT funding for CI-IPOP research unit (PEst-OE/SAU/UI0776/201). co-financed by the European Regional Development Fund under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728). FCT is co-financed by European Social Fund (ESF) under Human Potential Operation Programme (POPH) from National Strategic Reference Framework (NSRF). The funders did not play a role in the study design, data collection or decision to publish.
publishDate 2018
dc.date.none.fl_str_mv 2018-12-01
2018-12-01T00:00:00Z
2023-01-05T22:13:24Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/147031
url http://hdl.handle.net/10362/147031
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2045-2322
PURE: 16666184
https://doi.org/10.1038/s41598-018-30421-w
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833596851012501504